<DOC>
	<DOCNO>NCT00392054</DOCNO>
	<brief_summary>The purpose study determine whether catheter-based pulmonary vein isolation superior antiarrhythmic drug first line therapy patient symptomatic paroxysmal recurrent atrial fibrillation previously treat therapeutic dos antiarrhythmic drug .</brief_summary>
	<brief_title>First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs Atrial Fibrillation Treatment ( The RAAFT Study )</brief_title>
	<detailed_description>Atrial fibrillation ( AF ) common arrhythmia encounter clinical practice estimate affect 2.2 million people United States . AF major cause stroke , adversely affect quality life , associate increased mortality . Despite advance antiarrhythmic drug therapy , AF continue associate significant morbidity . Although antiarrhythmic drug therapy currently consider first-line option , recent data indicate 35 % Patients recurrence AF despite best antiarrhythmic drug ( AAD ) therapy , 30 % Patients discontinue drug adverse reaction . Furthermore , although recent trial indicate equivalence rhythm rate control strategies patient population , 25-35 % Patients AF rate control continue activity limiting symptom . Newer measure prevent , treat potentially cure AF need . Seminal work Haissaguerre replicate Chen show majority AF initiate ectopic focus find primarily pulmonary vein ( PV ) . Experience catheter-based Maze technique lead observation open door effective practical catheter-based cure AF . In response difficulty focal ablation , alternate strategy develop seek electrically isolate Pulmonary Veins atrial tissue . Empirical PV isolation target PV 's without regard initiation ectopic beat . The goal create entrance block PV . Multipolar circular catheter basket catheter develop facilitate identification electrical connection present junction atrium PV , radiofrequency energy apply circumferential fashion entrance block achieve . Relative focal ablation , circumferential PV isolation simpler perform , complete without induce AF , short procedure time , low incidence PV stenosis . Comparison : Patients ablation achieve entrance and/or exit block pulmonary vein , compare patient receive antiarrhythmic drug give accordance ACC/AHA/ESC 2006 Guidelines Management patient AF .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<criteria>1 . Age &gt; 18 â‰¤ 75 year old . 2 . Symptomatic , recurrent paroxysmal AF lasting &gt; 30 second ( least 4 episode within prior 6 month ) . At least one episode must document Holter,12lead ECG , event monitor rhythm strip . 1 . Documented LVEF &lt; 40 % . 2 . Documented leave atrial diameter &gt; 5.5cm . 3 . Moderate severe LVH ( LV wall thickness &gt; 1.5cm ) . 4 . Documented valvular disease , coronary heart disease ( define presence &gt; 70 % stenosis coronary artery documentation active myocardial ischemia ) , postCABG , postoperative cardiac surgery peripheral artery disease . 5 . Documented AF electrical cardioversion full therapeutic antiarrhythmic drug therapy cardioversion prescribe . 6 . Untreated hypothyroidism hyperthyroidism . Patients euthyroid thyroid hormone replacement therapy acceptable . 7 . Contraindication use sotalol , dofetilide 1C antiarrhythmic drug ( liver enzymes serum creatinine outside upper normal lab value , e.g . &gt; 3 time ULN 2 abnormal lab value ) . 8 . Previous leave heart ablation procedure , either surgery percutaneous catheter , atrial fibrillation . 9 . Current enrollment another investigational drug device study . 10 . Presence condition investigator feel would problematic would restrict limit participation Patient entire study period . 11 . Absolute contraindication use heparin warfarin . 12 . Increase risk bleeding , current peptic ulceration , proliferative diabetic retinopathy , history severe systemic bleeding , history bleed diathesis coagulopathy . 13 . Severe pulmonary disease e.g . restrictive pulmonary disease , chronic obstructive disease ( COPD ) . 14 . Documented intraatrial thrombus , tumor , another abnormality preclude catheter introduction . 15 . Previous use full therapeutic dose antiarrhythmic drug , include amiodarone , propafenone , flecainide , sotalol , quinidine . 16 . Pacemaker Implantable Cardioverter Defibrillator . 17 . Women positive pregnancy test . 18 . Evidence active cardiac systemic infection . 19 . Medical condition limiting expect survival less one year .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Paroxysmal</keyword>
	<keyword>Pulmonary Vein Isolation</keyword>
	<keyword>Ablation Catheter</keyword>
	<keyword>Anti-arrhythmic Drug Therapy</keyword>
	<keyword>First Line Therapy</keyword>
</DOC>